FAN1 Genotype

If you have chronic kidney disease that no one has been able to explain, part of the answer may sit in your DNA. A specific inherited fault in a gene called FAN1 (Fanconi anemia-associated nuclease 1) can quietly damage the kidneys over decades, often surfacing as kidney failure in a person's forties.

This test reads the two copies of the FAN1 gene you inherited, one from each parent. It tells you whether you carry the specific combination that causes disease, something a routine kidney panel cannot reveal.

What FAN1 Does in Your Cells

FAN1 holds the instructions for a protein that fixes a particularly nasty kind of DNA damage, where the two strands of the DNA ladder become glued together and can no longer separate so the cell can copy itself. The protein is a nuclease, meaning it cuts DNA at precise spots to allow repair.

This gene is active across many tissues, including the brain, and its job is keeping the genome intact. It does this work inside cells rather than releasing something into the bloodstream, which is why the test reads your DNA directly instead of measuring a level. When both copies are faulty, cells lose this repair capacity, and the tissues most sensitive to that loss, especially the kidneys, are the ones that suffer.

Why You Need Two Faulty Copies

FAN1-related kidney disease is recessive, which means it takes two faulty copies to cause it. If you inherited one working copy and one faulty copy, you are a carrier, and carriers almost always stay healthy.

This pattern is clear in the families studied. In one large Hungarian family, relatives who carried a single faulty copy had completely normal kidney and liver blood tests, while those with two faulty copies developed serious disease. So the single most important thing your result tells you is not just which variant you have, but whether you have one copy or both.

Kidney Disease: The Clearest Link

The best-established consequence of two faulty FAN1 copies is karyomegalic tubulointerstitial nephropathy (a kidney disease named for the swollen, oversized nuclei that appear inside kidney cells). It progresses slowly and tends to announce itself in mid-adulthood.

In the largest group studied so far, 56 genetically confirmed families carrying 38 different FAN1 variants, the disease typically showed up at a median age of 38.5 years, and kidneys failed at a median age of 45. Because the decline is gradual, many people go years with unexplained kidney damage before the cause is found.

Beyond the Kidneys

This is a whole-body condition, not just a kidney one. People with two faulty copies frequently have raised liver enzymes, recurrent infections, and lung disease, and the enlarged-nuclei changes can appear in organs other than the kidney.

The lung involvement carries real weight. In the multicenter cohort, just over a quarter of affected people had died, at a median age of 55, and lung disease was a major contributor even after dialysis or transplant. One particular variant, p.W707X, stood out: people carrying it were roughly eight times as likely to develop lung complications and had about three times the risk of dying earlier.

A Modifier of Huntington's Disease

FAN1 also plays a second, very different role. In Huntington's disease, an inherited neurological condition, FAN1 variants do not cause the disease but shift when it begins.

The mechanism is repeat instability, where a stretch of repeated DNA in another gene keeps expanding in the body's cells over a lifetime, and FAN1 helps restrain that expansion. Damaging FAN1 variants, which cluster in the DNA-cutting parts of the protein, are linked mainly to earlier onset, while some other variants that raise FAN1 activity can delay it. This is an active area of research, and the effect can differ between blood cells and brain tissue, so a FAN1 result is not a straightforward predictor of Huntington's timing.

The Colorectal Cancer Question

You may see FAN1 described as a colorectal cancer gene. The story is more nuanced than that label suggests, and it is worth understanding why two credible studies seem to disagree.

A 2015 study found FAN1 variants in about 3% of a hand-picked group: families with strong colorectal cancer histories who did not have the more common inherited cause. That looked promising. But a later analysis of more than 5,000 people referred for cancer risk assessment found faulty FAN1 copies in only about 0.35% overall, no more often than in the general population, and no extra cancer in the relatives tested.

These findings are not actually in conflict. The early 3% figure came from an unusually high-risk, narrow slice of families, which can concentrate rare variants that turn out not to raise risk once you look at the broader population. Studies of early-onset breast cancer families point the same way, finding no increased risk from the FAN1 variants they examined. The reasonable read today is that FAN1 is not an established major cancer gene, and a carrier result should not be treated as a cancer diagnosis.

What This Test Is Not

Despite the gene's full name, this is not a test for Fanconi anemia. People missing the entire FAN1 gene did not show the chromosome fragility or clinical features of Fanconi anemia, so the naming is a source of confusion rather than a shared diagnosis.

Links between FAN1 and psychiatric conditions such as schizophrenia, autism, and bipolar disorder are also preliminary. They come from studies of common gene variants in specific populations, a different question from the rare, disease-causing variants behind the kidney disease, and the researchers themselves called for larger studies before drawing conclusions.

A One-Time Result You Act On for Years

Your FAN1 genotype was set at conception and never changes, so unlike a cholesterol or blood sugar number, there is no trend to track and no reason to repeat the test itself. A single accurate result is yours for life.

The value comes from what you do with it over the following years. If you carry two disease-causing copies, the tracking shifts to your kidneys and liver: regular checks of kidney filtration (through creatinine, cystatin C, and eGFR, the estimated glomerular filtration rate that shows how well your kidneys clear waste) and liver enzymes let you catch decline early. A sensible cadence is at least annual monitoring, and more often if numbers start to move or you are making treatment decisions.

When a Result Can Mislead You

Genetic testing has its own traps that are different from an ordinary blood test. The most important ones affect whether a result is complete and correctly interpreted:

• Panel coverage: an assay only finds the variants it is designed to look for, and FAN1 is not on every genetic panel, so a negative result does not rule out a rare variant the test never examined.
• Uncertain-significance variants: labs sometimes report a change whose meaning is not yet known, which is neither a clean all-clear nor a confirmed problem.
• Ancestry: some variants are common in one population and rare in another, so the meaning of a result depends partly on your genetic background.
• Technical limits: analyzing DNA from preserved tissue or relying on some PCR methods can occasionally miss one of the two copies, so an unexpected result may warrant confirmation by a second method.

What to Do With an Unexpected Result

If the report shows two disease-causing copies, especially alongside unexplained kidney disease, the next step is a nephrologist and a genetics professional working together. They may order kidney and liver function panels more aggressively, consider a kidney biopsy that can show the characteristic enlarged nuclei, and set a monitoring schedule for filtration and liver enzymes.

If the report shows a single copy, the practical implications are mostly for family planning rather than your own kidney health. A chip-based result that is surprising is worth confirming with sequencing before you act on it. In every case, the finding should prompt a conversation with biological relatives, because siblings and children may share the variant and benefit from targeted testing.